Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Gyre Therapeutics, Inc. (GYRE) had Revenue of $105.76M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$105.76M
Net Income	$12.09M
Cost of Goods Sold	$3.88M
Gross Profit	$101.87M
Operating Expenses	$89.59M
Operating Income	$16.16M
Non-Operating Income/Expense	$7.05M
Pre-Tax Income	$23.22M
Normalized Pre-Tax Income	$23.22M
Income after Taxes	$17.90M
Income from Continuous Operations	$17.90M
Consolidated Net Income/Loss	$17.90M
Normalized Income after Taxes	$17.90M
EBIT	$16.16M
EBITDA	$17.75M
Weighted-Average Shares Outstanding (Basic)	85.09M
Weighted-Average Shares Outstanding (Diluted)	102.29M
Earnings per Share (EPS) (Basic)	$0.14
Earnings per Share (EPS) (Diluted)	$0.05
Balance Sheet Financials
Current Assets	$64.79M
Property, Plant, and Equipment	$23.88M
Long-Term Assets	$60.62M
Total Assets	$125.41M
Current Liabilities	$19.52M
Long-Term Debt	--
Long-Term Liabilities	$7.49M
Total Liabilities	$27.00M
Common Equity	$98.40M
Tangible Shareholders Equity	$96.70M
Shareholders Equity	$98.40M
Common Shares Outstanding	86.31M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-3.64M
Cash Flow from Investing Activities	$-19.88M
Cash Flow from Financial Activities	$2.10M
Beginning Cash	$33.51M
End Cash	$11.81M
Increase/Decrease in Cash	$-21.70M
Stock-Based Compensation	$0.83M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.32
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	--
Gross Margin	96.33%
Operating Margin	15.28%
EBIT Margin	15.28%
EBITDA Margin	16.78%
Pre-Tax Profit Margin	21.95%
Profit Margin	11.43%
Free Cash Flow	$-5.55M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.84
Inventory Turnover	0.61
Receiveable Turnover	4.27
Days Sales in Receivables	85.52
Return on Equity	18.19%
Return on Tangible Equity	18.51%
Return on Assets	14.27%
Return on Investments	18.19%
Book Value Per Share	$1.14
Free Cash Flow per Share	$-0.05
Operating Cash Flow per Share	$-0.04

Data from Zacks Investment Research, Inc.